Breaking News

Financial Reports: Teva

By Gil Roth | February 6, 2014

Generic exclusivity boosts 4Q revenues

Teva 4Q13

4Q Revenues: $5.4 billion (+3%)

4Q Earnings: $380 million (+19%)

FY Revenues: $20.3 billion (flat)

FY Earnings: $1.3 billion (-34%)

Comments: Generic revenues were up 1% in 4Q to $2.7 billion (including $163 million in third-party API sales), with U.S. revenues growing 14% to $1.2 billion, driven by exclusive launches of generics for Niaspan, Temodar, Cymbalta and Tobi. Sales of specialty medicines grew 5% in 4Q to $2.2 billion, driven by Copaxone and Treanda. Copaxone revenues were up 21% in 4Q to $1.1 billion. OTC revenues grew 10% in 4Q to $529 million. For FY13, generic revenues fell 5% to $9.9 billion and specialty medicines grew 3% to $8.4 billion. The drop in generic revenues is largely attributable to the loss of royalties for generic Lipitor, as well as the loss in exclusivity for generic Lexapro and Actos/Actoplus met. Copaxone revenues for FY were up 8% to $4.3 billion, while Treanda sales rose 3% to $709 million.

Related Contract Manufacturing:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.